Primes/Preconditions Cancer Patients with Solid Tumors Before Administering CAR T-Cell Immunotherapy
This RNA-nanoparticle vaccine enables CAR T immunotherapeutic to infiltrate solid tumors by priming patients before administering treatment. Chimeric antigen receptor (CAR) T cell therapy has revolutionized cancer treatment, particularly for hematologic cancers, such as leukemia, lymphoma, and multiple myeloma. However, its effectiveness in treating solid tumors is limited due to the need for lymphodepletion (LD) conditioning, which causes significant side effects such as increased infection risk, low blood counts, and fatigue. Additionally, many solid tumors are refractory and do not respond to CAR T cell therapy due to insufficient levels of surface antigens. This creates a critical need for safer and more effective preconditioning methods and strategies to make refractory tumors responsive to CAR T cell therapy. This innovative approach aims to reprogram the immune system and overcome resistance to existing treatments.
Researchers at the University of Florida have developed an RNA nanoparticle vaccine that can be loaded with RNAs encoding tumor neoantigens. These nanoparticles are designed to create personalized cancer vaccines in combination with immunotherapy, preconditioning patients for CAR T cell therapy. The nanoparticles create an immunological environment to promote T cell trafficking and activation in solid tumors, transforming "cold" tumors into "hot" tumors recognized by the immune system. This represents a paradigm shift in preparing patients for CAR T cell therapy and expands the potential patient population.
Application
Administers a nanoparticle composition to precondition patients for CAR T cell therapy and enhance the treatment's efficacy
Advantages
- Tailored to individual patient's tumor neoantigens, enabling a personalized treatment
- Significantly increases cytotoxic and memory T cells for an enhanced immune response by promoting T cell trafficking and activation in solid tumors, improving treatment outcomes
- Reduces tumor growth in refractory solid tumors by enabling their responsiveness to CAR T cell therapy, broadening the scope of treatable cancers, and offering a promising solution for patients who are resistant to checkpoint inhibitors
Technology
The vaccine uses nanoparticles with a positively charged surface and multiple nucleic acid layers, each positioned between cationic lipid bilayers. These nanoparticles are administered at least one day prior to CAR T cell therapy, creating a favorable immunological environment for T cell activation and trafficking. The nanoparticles can also encode surface antigens, transforming refractory tumors into ones that respond to CAR T cell therapy. This approach may enhance the efficacy of CAR T-cell therapy and reduce reliance on conventional lymphodepletion, potentially offering a safer and more broadly applicable treatment strategy for patients with cancer.
Brochure
